Our Focus Areas
At Chugai in Europe, we have extensive experience in our core therapy areas of haemophilia, oncology, and rheumatology, providing treatments for unmet medical needs. In our ambition to be a top innovator, we also seek to develop innovative solutions that explore the potential of digital, complementing our existing portfolio and further supporting the medical community. We work on solutions originating from Chugai Pharmaceutical Co., Ltd. research, as well as on products developed with our wider network of partners. We have extensive experience of working in partnership, and pride ourselves on the flexibility and capabilities we can offer.
Haemophilia
Chugai Pharmaceutical Co., Ltd. has proven strengths and accomplishments in antibody drug discovery research and investigation into a therapy for haemophilia started back in 2002. Together with our partners at Roche, we are consistently striving to be a trusted member of the European haemophilia community, engaging with a wide range of stakeholders to help people with haemophilia.
Oncology & Supportive Care
Chugai Pharmaceutical Co., Ltd. has a long history in oncology, with its first cancer treatment launched in 1975. Since then, Chugai Pharmaceutical Co., Ltd. has been recognised as a leader in cancer management in Japan. In Europe, we are committed to utilising our unique strengths in science and technology, and our partnerships with Roche and Helsinn, to improve the quality of cancer care and support patients through their cancer journey.
Rheumatology
Rheumatological diseases cover a broad spectrum of inflammatory conditions and since the mid-1960s, Chugai Pharmaceutical Co., Ltd. has been at the forefront of advancing immune therapy research. To support their immunotherapy research, we are dedicated to working with Roche and our wider network of partners in Europe to expand the potential of new biologic therapies, to help improve the lives of patients.
Digital Therapeutics
Together with our colleagues in Japan, we are committed to transforming our business by using digital technologies to make Chugai Pharmaceutical Co., Ltd. a top innovator in the provision of society-changing healthcare solutions. To achieve this digital vision for 2030, we seek to form strong partnerships with the European innovation ecosystem to explore digital solutions that support our core therapy areas.
Our portfolio in Europe
C-GB-00000897 | Date of Preparation: November 2023
